

INTRODUCTION

- Collaborations in renal cell carcinoma research** S5
L.A. Wood, M.A.S. Jewett

CONFERENCE SUMMARY

- Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma Forum** S6
L.A. Wood, B. Escudier, N. Reaume

REVIEWS

- Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists** S13
D.L. Lim, R. Ko, S.E. Pautler

- Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma** S21
K.A. Furge, K. Dykema, D. Petillo, M. Westphal, Z. Zhang, E.J. Kort, B.T. Teh

- Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma** S28
A.K. Kapoor, S.J. Hotte

- Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines** S34
S.J. Hotte, A.K. Kapoor

- Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects** S41
C. Kollmannsberger, D. Soulieres, R. Wong, A. Scalera, R. Gaspo, G. Bjarnason

- Locally advanced renal cell carcinoma** S55
M. Al Otaibi, S. Tanguay

- New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer** S62
R.A. Rendon

Publications Mail Agreement no. 41387051. Return undeliverable Canadian copies to *CUAJ*, 1155 University, Suite 1014, Montréal QC H3B 3A7; journal@cua.org.

Numéro de convention poste-publications 41387051. Retourner toutes copies canadiennes non livrées au *JAUC*, 1155 rue Université, Bureau 1014, Montréal, QC H3B 3A7; journal@cua.org.

USPS #024-122. USPS periodical postage paid at Champlain, NY. Return other undeliverable copies to IMS of NY, 100 Walnut St., #1, PO Box 1518, Champlain NY 12919-1518.

TABLE OF CONTENTS

DEBATE

Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists S69

L. Klotz

A medical oncologist is the most qualified specialist to provide systemic therapy for patients with advanced renal cell carcinoma S70

P. Venner

EPILOGUE

Renal cell carcinoma: currently the most interesting genitourinary malignancy S74

L.A. Wood, M.A.S. Jewett

All editorial matter in *CUAJ* represents the opinions of the authors and not necessarily those of the Canadian Urological Association. The CUA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CUAJ*.